AKT1 and cancer: It is important to remind that PTEN functions in a dosage-dependent manner during tumor development and that moderate PTEN reduction, without complete loss, has been reported to activate the PI3K/Akt pathway and to be associated with chemoresistance and cancer progression [22,23].